These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

270 related items for PubMed ID: 8328203

  • 1. The role of type-1 plasminogen activator inhibitor in failure of thrombolytic therapy with recombinant tissue plasminogen activator.
    Huber K, Beckmann R, Rauscha F, Probst P, Kaindl F, Binder BR.
    Z Kardiol; 1993; 82 Suppl 2():195-200. PubMed ID: 8328203
    [Abstract] [Full Text] [Related]

  • 2. Relationship of plasminogen activator inhibitor-1 levels following thrombolytic therapy with rt-PA as compared to streptokinase and patency of infarct related coronary artery.
    Paganelli F, Alessi MC, Morange P, Maixent JM, Lévy S, Vague IJ.
    Thromb Haemost; 1999 Jul; 82(1):104-8. PubMed ID: 10456462
    [Abstract] [Full Text] [Related]

  • 3. Influence of cardiac output on peak t-PA plasma levels in patients receiving thrombolytic therapy with recombinant tissue-type plasminogen activator--correlation with patency rate.
    Huber K, Beckmann R, Probst P, Rauscha F, Kaindl F, Binder BR.
    Thromb Haemost; 1993 Jan 11; 69(1):45-9. PubMed ID: 8446938
    [Abstract] [Full Text] [Related]

  • 4. In vitro clot lysis as a potential indicator of thrombus resistance to fibrinolysis--study in healthy subjects and correlation with blood fibrinolytic parameters.
    Colucci M, Scopece S, Gelato AV, Dimonte D, Semeraro N.
    Thromb Haemost; 1997 Apr 11; 77(4):725-9. PubMed ID: 9134650
    [Abstract] [Full Text] [Related]

  • 5. Plasma TAFI and soluble CD40 ligand do not predict reperfusion following thrombolysis for acute myocardial infarction.
    Cruden NL, Graham C, Harding SA, Ludlam CA, Fox KA, Newby DE.
    Thromb Res; 2006 Apr 11; 118(2):189-97. PubMed ID: 16055173
    [Abstract] [Full Text] [Related]

  • 6. Evaluation of tissue plasminogen activator and plasminogen activator inhibitor-I levels in acute myocardial infarction.
    Yamada S, Yamada R, Ishii A, Ashikawa K, Kawamitsu H, Fujita K.
    J Cardiol; 1996 Apr 11; 27(4):171-8. PubMed ID: 8642503
    [Abstract] [Full Text] [Related]

  • 7. Streptokinase and rt-PA activate platelets by a different way: implications on the rethrombosis rate after their administration in myocardial infarction.
    Parise P, Hauert J, Iorio A, Callegari P, Agnelli G.
    J Lab Clin Med; 1995 Feb 11; 125(2):212-21. PubMed ID: 7531212
    [Abstract] [Full Text] [Related]

  • 8. Plasminogen activator inhibitor type-1 determines plasmin formation in patients with ischaemic heart disease.
    Pedersen OD, Gram J, Jespersen J.
    Thromb Haemost; 1995 May 11; 73(5):835-40. PubMed ID: 7482412
    [Abstract] [Full Text] [Related]

  • 9. Procoagulant properties of intravenous staphylokinase versus tissue-type plasminogen activator.
    Okada K, Lijnen HR, Moreau H, Vanderschueren S, Collen D.
    Thromb Haemost; 1996 Dec 11; 76(6):857-9. PubMed ID: 8972000
    [Abstract] [Full Text] [Related]

  • 10. Correlation between baseline plasminogen activator inhibitor levels and clinical outcome during therapy with tissue plasminogen activator for acute myocardial infarction.
    Sane DC, Stump DC, Topol EJ, Sigmon KN, Kereiakes DJ, George BS, Mantell SJ, Macy E, Collen D, Califf RM.
    Thromb Haemost; 1991 Mar 04; 65(3):275-9. PubMed ID: 1904653
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Thrombolytic and haemorrhagic effects of bolus doses of tissue-type plasminogen activator and a hybrid plasminogen activator with prolonged plasma half-life (K2tu-PA: CGP 42935).
    Agnelli G, Pascucci C, Nenci GG, Mele A, Bürgi R, Heim J.
    Thromb Haemost; 1993 Aug 02; 70(2):294-300. PubMed ID: 8236138
    [Abstract] [Full Text] [Related]

  • 15. Transmyocardial fibrinolytic activity in patients with unstable angina pectoris.
    Daniel WC, Meidell RS, Hillis LD, Lange RA.
    Coron Artery Dis; 1996 Jan 02; 7(1):45-9. PubMed ID: 8773432
    [Abstract] [Full Text] [Related]

  • 16. Aspirin does not potentiate effect of suboptimal dose of the thrombin inhibitor inogatran during coronary thrombolysis.
    Chen LY, Nichols WW, Mattsson C, Teger-Nilson AC, Wallin R, Saldeen TG, Mehta JL.
    Cardiovasc Res; 1995 Dec 02; 30(6):866-74. PubMed ID: 8746200
    [Abstract] [Full Text] [Related]

  • 17. [Platelet activation in the early phases of acute myocardial infarction].
    Salvioni A, Giraldi F, Assanelli E, Lauri G, Grazi M, Pardea S, Marenzi G.
    Cardiologia; 1998 Aug 02; 43(8):825-32. PubMed ID: 9808873
    [Abstract] [Full Text] [Related]

  • 18. [New substances and dosages for thrombolysis in acute myocardial infarct].
    Zeymer U, Neuhaus KL.
    Z Kardiol; 1993 Aug 02; 82 Suppl 2():137-41. PubMed ID: 8328192
    [Abstract] [Full Text] [Related]

  • 19. [Intravenous infusion of recombinant tissue-type plasminogen activator (rt-PA) and urokinase in acute myocardial infarct: intermediate results of the G.A.U.S. study (German Activator Urokinase Study)].
    Neuhaus KL, Tebbe U, Gottwik M, Weber MA, Feuerer W, Niederer W, Haerer W, Praetorius F, Grosser KD, Huhmann W.
    Klin Wochenschr; 1988 Aug 02; 66 Suppl 12():102-8. PubMed ID: 3126339
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.